Navigation Links
Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
Date:8/25/2009

SEATTLE While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor. These findings by Christopher Li, M.D., Ph.D., and colleagues at Fred Hutchinson Cancer Research Center were published online Aug. 25 in the journal Cancer Research.

Hormonal therapy with drugs like tamoxifen is one of the most common treatments for breast cancer because it has been shown to reduce the risk of dying from the disease but, as this study suggests, it does have risks.

Comparing breast-cancer patients who received the estrogen-blocking drug tamoxifen to those who did not, the researchers found that while the drug was associated with a 60 percent reduction in estrogen receptor-positive, or ER positive, second breast cancer the more common type, which is responsive to estrogen-blocking therapy it also appeared to increase the risk of ER negative second cancer by 440 percent. "This is of concern, given the poorer prognosis of ER-negative tumors, which are also more difficult to treat," said Li, an associate member of the Hutchinson Center's Public Health Sciences Division.

These findings confirm preliminary research by Li and colleagues, published in 2001, which was the first to suggest a link between long-term tamoxifen use and an increased risk of ER-negative second cancers. "The earlier study had a number of limitations. For example, we did not have information on the duration of tamoxifen therapy the women received," Li said. "The current study is larger, is based on much more detailed data, and is the first study specifically designed to determine whether tamoxifen use among breast cancer survivors influences their risk of different types of second breast cancers," Li said.

This new study assessed history of tamoxifen use among 1,103 breast cancer survivors from the Seattle-Puget Sound region who were initially diagnosed with ER positive breast cancer between the ages of 40 and 79. Of these, 369 of the women went on to develop a second breast cancer. Nearly all of the women in the study who took adjuvant hormonal therapy used tamoxifen specifically. Detailed information about tamoxifen use was ascertained from telephone interviews and medical record reviews.

While the study confirmed a strong association between long-term tamoxifen therapy and an increased risk of ER-negative second cancer, it does not suggest that breast cancer survivors should stop taking hormone therapy to prevent a second cancer, Li said.

"It is clear that estrogen-blocking drugs like tamoxifen have important clinical benefits and have led to major improvements in breast cancer survival rates. However, these therapies have risks, and an increased risk of ER negative second cancer may be one of them. Still, the benefits of this therapy are well established and doctors should continue to recommend hormonal therapy for breast cancer patients who can benefit from it," Li said.


'/>"/>

Contact: Kristen Woodward
kwoodwar@fhcrc.org
206-667-5095
Fred Hutchinson Cancer Research Center
Source:Eurekalert

Related medicine news :

1. New research: Consumption of sugar substitutes assists in long-term weight control
2. Long-term exercise, healthy eating habits in young adults: U-M study
3. Attendance on Demand, Inc. Hosts Free Webinar Top 5 Tools to Control Labor Costs for Long-Term Healthcare Professionals 2:30pm EDT August 26, 2009
4. Long-Term Care Leader Joins 3 in 4 Need More Campaign to Promote LTC Protection for All
5. New Health Reform Campaign Will Support Long-Term Care for All, Because 3 in 4 Need More
6. MU expert offers tips for finding the best long-term care
7. LG Electronics Introduces New Flat-Panel HDTVs Designed Specifically for Long-Term Care Facilities
8. Long-term health and social outcomes for neuroblastoma survivors
9. Blood Transfusions Not Linked to Long-Term Problems
10. Actuaries: Federal Long-Term Care Legislation Falls Short on Coverage Goals
11. Energy and Commerce Committee Advances Long-Term Services and Supports in Health Care Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... of individuals with HIV because it is not known to have significant interactions ... favorable effects to both lower cholesterol levels and dampen inflammation in the bloodstream. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... that over the last decade, student well-being has seriously declined. "When disenfranchised youth ... formal education, join the Islamic State to turn the historic multi-ethnic and multi-religious ...
(Date:4/24/2017)... ... April 24, 2017 , ... Life of Purpose Treatment is proud to ... will be held at 7:30 pm on May 10th at the University Auditorium. , ... Sister Hazel, will support the UF Collegiate Recovery Community (UFCRC). The concert will kick ...
(Date:4/23/2017)... ... 23, 2017 , ... Altura Communication Solutions, a nationwide provider ... certification and SMB specialization. Altura is now qualified to sell, install and ... Select Certification, Altura fulfilled the training and exam requirements for the Cisco Small ...
(Date:4/22/2017)... ... April 22, 2017 , ... The San Juan Capistrano summer camp team at the ... the need for summer camps to provide physical activities for all campers. To read the ... Summer Camps , With an increase in specialty camps that focus on what the report ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
(Date:4/19/2017)... LONDON , April 19, 2017 ... to stimulate an immune response in pets such ... vaccine products are of various types such as ... Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. ... such as virus or bacteria, which have been ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: